06:48 AM EDT, 10/09/2024 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday that the US Food and Drug Administration had lifted the clinical hold on its investigational new drug application for the phase 1 trial of its experimental drug, OCU200, a recombinant fusion protein used to treat diabetic macular edema.

The company said it also plans to explore additional uses for OCU200, including potentially treating diabetic retinopathy and wet age-related macular degeneration.